Board advances revised compounding rules to 15‑day public comment after hours of debate

The board (full name not specified in the transcript) voted on Jan. 8 to release revised regulations governing compounding of sterile and nonsterile drug preparations, hazardous drugs and radiopharmaceuticals for a 15‑day public comment period and to delegate follow‑up review authority to committee members.

Board president Sang Oh said the board is “a consumer protection agency charged with administering and enforcing pharmacy law,” and emphasized the board’s public‑protection mandate as members discussed changes intended to align state rules with national standards while clarifying California‑specific requirements.

Why it matters: The proposal responds to updates in United States Pharmacopeia (USP) compounding chapters and aims to reduce confusion among licensees about how federal USP standards and California regulations interact. The changes affect pharmacies, hospital compounding units, and other facilities that prepare compounded medications, with downstream effects for patients who rely on compounded sterile products and specialized formulations such as flavored pediatric suspensions and certain patient‑administered preparations.

Most important actions and outcomes

- At the meeting’s close, a motion by board member Maria (mover) and seconded by board member KK passed unanimously to: (1) accept staff responses to comments received during the 30‑day comment period consistent with the board’s discussion; (2) approve the recommended modified regulatory text for a 15‑day public comment period; and (3) delegate authority to members of the Enforcement and Compounding Committee (members Serpa and Barker, and the committee chair working with staff) to review additional comments received during that 15‑day period and advise the full board on final language. The motion passed on a recorded voice vote with all present members voting yes.

Scope of the revisions

Staff and board members reviewed multiple areas of the proposed text. Key proposals and clarifications discussed at the meeting include:

- Nonsterile compounding and flavoring: The package creates a narrowly tailored path for pharmacies that only add flavoring agents to commercially available products. The proposed language would treat simple flavoring under a streamlined set of SOP and recordkeeping requirements rather than the full nonsterile compounding regime. Board presenters said that flavoring remains “compounding” under federal law and that the state text does not exempt flavoring from the compounding definition; it instead limits which additional nonsterile regulatory provisions apply. Several public commenters representing pharmacies and flavoring vendors asked for clearer examples of the records and SOPs required under the streamlined path.

- Sterile compounding and immediate‑use flexibilities: The draft adds limited immediate‑use flexibilities for sterile compounding when facilities experience equipment or environmental failures. Staff recommended allowing immediate‑use compounding for up to 48 hours under specified conditions and up to 120 hours in designated critical access hospitals after remediation attempts are unsuccessful. Hospital commenters, including UCHealth and representatives of large health systems, urged longer allowances in some cases (one asked for up to seven business days) because of vendor and parts availability in rural settings.

- Hazardous drugs (HD) and personal protective equipment: Staff narrowed the scope of certain handling prohibitions and clarified that wipe sampling is not universally required but should be considered and documented. The package proposes more flexibility for outer‑glove use in specific workflows and would adjust labeling and glove‑availability language for drugs administered within health care facilities. Commenters from hospital systems and compounding associations raised cost and operational concerns about a proposed requirement to change outer gloves between each different HD preparation; several speakers asked the board to remove or further narrow that requirement.

- Radiopharmaceuticals and reporting windows: Proposed changes include deleting a redundant prohibition on compounding in SRPAs and lengthening the board notification window for certain events from 72 to 96 hours to align with other sections.

- Category 503A/503B and bulk substances: The board reiterated that it intends to follow FDA determinations on which active pharmaceutical ingredients are permitted (category 1 bulk list) and USP procedures on how to compound them. Multiple commenters argued that California’s testing, documentation and stability requirements for using category 1 APIs go beyond what is practicable for many compounding pharmacies; staff responded that some California provisions restate federal or USP requirements for clarity and that the board is not attempting to add additional federal restrictions.

Major points of discussion from board members and the public

Board members and staff debated language in several areas that drew substantial public comment: whether the regulations should require reporting of “adverse drug experiences” in specific nonsterile sections (some board members proposed removing that phrase from several subsections); how to define and document when a product is an “essentially a copy” of a commercially available product and what pharmacist verification is required; the appropriate length of an immediate‑use allowance after facility failures; and operational details such as pass‑through doors, temperature monitoring language (staff recommended “typically maintained” to allow limited excursions with SOPs), and how to phrase a requirement to “offer” protective gloves to patients.

Public comment: Dozens of clinicians, health‑system pharmacists, compounding pharmacy owners, trade groups and patients spoke. Themes included requests for clearer, narrower language on flavoring exemptions; opposition to glove‑change requirements due to cost and supply concerns; calls for clearer pathways for patient access to sterile therapies such as nebulized glutathione and injectable methylcobalamin; and requests from hospital systems for broader immediate‑use allowances in some emergency situations. The California Medical Association urged the board to make explicit that the regulations do not apply to physicians; the board said other healing‑arts boards retain jurisdiction over their licensees and that the Medical Board of California’s letter was in the record.

What the vote does and does not do

The board’s action authorizes staff to publish the next modified text for a 15‑day public comment period and delegates limited authority to committee members to review any additional comments received in that period and recommend final language. It does not adopt the regulations as final; it starts a shorter public comment window and preserves the board’s ability to revise text before final adoption. Staff and several board members emphasized that a longer comment period could jeopardize timing because the package must complete several control‑agency reviews before submission to the Office of Administrative Law.

Next steps and follow‑up items

- A second (staff‑proposed) modified text will be posted for 15 days; the board’s Enforcement and Compounding Committee members Serpa and Barker (with staff) will have delegated authority to screen comments and prepare recommendations to the full board.

- Staff will refine non‑substantive edits and address remaining typographical and cross‑reference issues. Board members asked staff to revisit the glove‑change language, pass‑through/pass‑through‑door language tied to building code references, adverse‑event wording in nonsterile sections, and the immediate‑use timeframes for facilities with limited vendor access.

- Members of the public and stakeholders were urged to submit written comments in the 15‑day period so the board can provide formal, trackable responses.

Ending note

Board members and staff framed the proceeding as an attempt to bring state regulations into clearer alignment with USP and FDA guidance while retaining California’s higher patient‑safety standards where they exist. The board passed the motion to proceed to a 15‑day comment period and directed committee members and staff to continue drafting refinements before returning to the full board for further action.